Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYLVER first-in-human study of GSK4418959 in dMMR/MSI-H solid tumors
jRCT2031240500Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of GSK4418959 in mismatch repair deficient solid tumor, Nonhematologic neoplasms, colorectal cancer (CRC) and 1 more (3 arms), sponsored by GSK. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events during DLT period and 2 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
GSK4418959
03
Conditions
mismatch repair deficient solid tumorNonhematologic neoplasmscolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2031240500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240500.